Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib for c-KIT mutated advanced melanoma
ISRCTN39058880Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in melanoma, mucosal melanoma (MM) and acral lentiginous melanoma (ALM), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Proportion of patients progression free at 6 months. Started Dec 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
melanomamucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ISRCTN39058880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39058880.